Filtered By:
Drug: Colchicine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 277 results found since Jan 2013.

Myocarditis and Pericarditis
Pericarditis typically presents with classic symptoms of acute sharp, retrosternal, and pleuritic chest pain. It can have several different underlying causes including viral, bacterial, and autoimmune etiologies. The mainstays of pericarditis treatment are nonsteroidal anti-inflammatory drugs and colchicine with glucocorticoids or other immunosuppressive drugs used for refractory cases and relapse. Myocarditis is an inflammatory disease of the cardiac muscle that is caused by a variety of infectious and noninfectious conditions. It mainly affects young adults (median age 30 –45 years), and men more than women. The clini...
Source: Primary Care: Clinics in Office Practice - August 26, 2023 Category: Primary Care Authors: Philip Hunter Spotts, Fan Zhou Source Type: research

Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies
ConclusionRemdesivir and baricitinib were approved for the treatment of hospitalized patients with severe COVID-19. Dexamethasone and methylprednisolone should be used with caution. Hydroxychloroquine, chloroquine, ivermectin, and azithromycin are ineffective for the treatment of the disease, and the other compounds presented uncertain results. Preclinical and clinical studies should not be analyzed alone, and their methodology ’s accuracy should also be considered. Regulatory agencies are responsible for analyzing the efficacy and safety of a treatment and must be respected as the competent authorities for this decision...
Source: European Journal of Clinical Pharmacology - April 20, 2023 Category: Drugs & Pharmacology Source Type: research

Colchicine and mortality outcomes in patients with coronavirus disease (COVID-19)
Eur J Intern Med. 2023 Feb 16:S0953-6205(23)00051-1. doi: 10.1016/j.ejim.2023.02.009. Online ahead of print.NO ABSTRACTPMID:36804360 | PMC:PMC9933322 | DOI:10.1016/j.ejim.2023.02.009
Source: European Journal of Internal Medicine - February 22, 2023 Category: Internal Medicine Authors: Mohammed I Danjuma Ridhima Kaul Tamader Alyaarabi Basant Elsayed Mohamed Elshafei Source Type: research

Effect of colchicine on clinical outcomes in COVID-19
Conclusion: Our study shows that colchicine did not improve outcomes in patients with severe COVID-19 infection.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Abdenneji, S., Fekih, W., Ben Krayen, I., El Ghoul, J. Tags: 10.01 - Respiratory infections and bronchiectasis Source Type: research

Efficacy of colchicine in patients with moderate COVID-19: A double-blinded, randomized, placebo-controlled trial
ConclusionColchicine was not found to have a significant beneficial effect on reducing mortality and the need for mechanical ventilation. However, a delayed beneficial effect was observed. Therefore, further studies should be conducted to evaluate the late benefits of colchicine. Clinical trial registrationClinical trial registration no: ClinicalTrials.gov Identifier: NCT04527562 https://www.google.com/search?client=firefox-b-d&q=NCT04527562.
Source: PLoS One - November 16, 2022 Category: Biomedical Science Authors: Motlabur Rahman Source Type: research

Coronavirus disease 2019 vaccination-related pericarditis: a single tertiary-center experience
Conclusion COVID-19 vaccine-related pericarditis typically manifest with mild clinical signs, in young male individuals, a few days after the second or third vaccine dose and are commonly characterized by a rapid complete recovery.
Source: Journal of Cardiovascular Medicine - November 12, 2022 Category: Cardiology Tags: Research articles: COVID-19 Source Type: research

Colchicine anti-inflammatory therapy for non-intensive care unit hospitalized COVID-19 patients: results from a pilot open-label, randomized controlled clinical trial
J Physiol Pharmacol. 2022 Jun;73(3). doi: 10.26402/jpp.2022.3.09. Epub 2022 Oct 22.ABSTRACTSystemic inflammation is a hallmark of severe coronavirus disease-19 (COVID-19). Anti-inflammatory therapy is considered crucial to modulate the hyperinflammatory response (cytokine storm) in hospitalized COVID-19 patients. There is currently no specific, conclusively proven, cost-efficient, and worldwide available anti-inflammatory therapy available to treat COVID-19 patients with cytokine storm. The present study aimed to investigate the treatment benefit of oral colchicine for hospitalized COVID-19 patients with suspected cytokine...
Source: Journal of Physiology and Pharmacology - October 27, 2022 Category: Drugs & Pharmacology Authors: M Z Haroon U Farooq S Ashraf S Zeb S Y Gillani S Malik R Ali R Irshad Z Mehmood Y Abbas A Masood A Ghafoor A T Khalil H Asif S Khan I D Ujjan R Nigar S Livingstone D A Pascual-Figal S Togni P Allergini A Riva A Khan Source Type: research

Efficient synthesis of novel colchicine-magnolol hybrids and evaluation of their inhibitory activity on key proteases of 2019-nCoV replication and acute lung injury
Nat Prod Res. 2022 Oct 27:1-10. doi: 10.1080/14786419.2022.2138870. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or 2019-nCoV), is a life-threatening infectious condition. Acute lung injury is a common complication in patients with COVID-19. 3-chymotrypsin-like protease (3CLpro) of 2019-nCoV and neutrophil elastase are critical targets of COVID-19 and acute lung injury, respectively. Colchicine and magnolol are reported to exert inhibitory effects on inflammatory response, the severe comorbidity in both COVID-19 and acute lung injur...
Source: Natural Product Research - October 27, 2022 Category: Biochemistry Authors: Liu-Yang Pu Zhiyue Li Feijuan Huang Limin Li Yucui Ma Min Ma Shengquan Hu Zhengzhi Wu Source Type: research